BI focuses on freshly mixed PCV2/M. hyo vaccines
Based on numerous studies, Boehringer Ingelheim Animal Health, a manufacturer of swine vaccines, has moved away from the development of a ready-to-use PCV2/M. hyo vaccine combination and focus on a freshly mixed approach only.
This approach, freshly mixing Porcine Circovirus type 2 (PCV2)/Mycoplasma hyopneumoniae (M. hyo) vaccines, is known as ‘FlexCombo’.
In a press release, the company states: “Although initial data was promising, it became evident over time that in this case, the ready-to-use design does not meet the high standards of efficacy and safety for which the company’s FlexCombo platform is known.”
The press release continues, “In essence, the company’s PCV2/M. hyo research programme revealed that the highest protection against both pathogens was observed for its vaccines when freshly mixed and applied in accordance with manufacturer recommendations.”
The’FlexCombo combination platform of mixable vaccines protects pigs against PCV2 and M. hyo with a single dose. In 2013, the company introduced the MycoFlex headspace bottle, a way to mix the two pig vaccines for their simultaneous application. The same concept is used for 3Flex, the mix of Ingelvac CircoFlex, Ingelvac MycoFlex and Ingelvac PRRS MLV which is presently licensed in North America and several Asian countries.
The 3Flex strategy has received good feedback in the countries where it has been launched, as fewer vaccinations mean increased animal welfare and an easy-to-use alternative for producers. Boehringer Ingelheim eventually hopes to achieve global availability for this threefold approach.
The press release states that the PCV2 vaccine is established globally as market leader for PCV2 vaccination while the M. hyo vaccine is the market leader in a number of key swine markets.
© Pinfoldphotos | Dreamstime.com – Solution Analysis Photo
